IS6994A - Arípíprazóllausn til gjafar um munn - Google Patents

Arípíprazóllausn til gjafar um munn

Info

Publication number
IS6994A
IS6994A IS6994A IS6994A IS6994A IS 6994 A IS6994 A IS 6994A IS 6994 A IS6994 A IS 6994A IS 6994 A IS6994 A IS 6994A IS 6994 A IS6994 A IS 6994A
Authority
IS
Iceland
Prior art keywords
oral administration
aripiprazole solution
aripiprazole
solution
oral
Prior art date
Application number
IS6994A
Other languages
English (en)
Other versions
IS2863B (is
Inventor
Parab Prakash
Chou Joyce
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23099862&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IS6994(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of IS6994A publication Critical patent/IS6994A/is
Publication of IS2863B publication Critical patent/IS2863B/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IS6994A 2001-04-25 2003-10-14 Arípíprazóllausn til gjafar um munn IS2863B (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28671801P 2001-04-25 2001-04-25
PCT/US2002/013048 WO2002085366A1 (en) 2001-04-25 2002-04-24 Aripiprazole oral solution

Publications (2)

Publication Number Publication Date
IS6994A true IS6994A (is) 2003-10-14
IS2863B IS2863B (is) 2013-12-15

Family

ID=23099862

Family Applications (1)

Application Number Title Priority Date Filing Date
IS6994A IS2863B (is) 2001-04-25 2003-10-14 Arípíprazóllausn til gjafar um munn

Country Status (36)

Country Link
US (1) US6977257B2 (is)
EP (2) EP2436384B2 (is)
JP (1) JP4401077B2 (is)
KR (1) KR100909329B1 (is)
CN (1) CN1512884B (is)
AR (1) AR033168A1 (is)
AT (1) ATE537831T1 (is)
AU (1) AU2002254722B2 (is)
BG (1) BG66177B1 (is)
BR (1) BR0208986A (is)
CA (1) CA2445276C (is)
CY (1) CY1112606T1 (is)
CZ (1) CZ306181B6 (is)
DK (1) DK1381367T3 (is)
EE (1) EE05581B1 (is)
ES (1) ES2377855T3 (is)
GE (1) GEP20053602B (is)
HR (1) HRP20030870B1 (is)
HU (1) HU230456B1 (is)
IL (2) IL158202A0 (is)
IS (1) IS2863B (is)
MX (1) MXPA03009728A (is)
MY (1) MY129350A (is)
NO (1) NO324606B1 (is)
NZ (1) NZ528550A (is)
PE (1) PE20021086A1 (is)
PL (1) PL206882B1 (is)
PT (1) PT1381367E (is)
RS (1) RS52082B (is)
RU (1) RU2295960C2 (is)
SK (1) SK287948B6 (is)
TW (1) TWI337865B (is)
UA (1) UA76144C2 (is)
UY (1) UY27273A1 (is)
WO (1) WO2002085366A1 (is)
ZA (1) ZA200307797B (is)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6770478B2 (en) * 2000-02-10 2004-08-03 The Regents Of The University Of California Erythrocytic cells and method for preserving cells
SI1542668T1 (sl) * 2002-08-20 2009-08-31 Bristol Myers Squibb Co Aripiprazol sestavljena formulacija in postopek
CA2540052C (en) * 2003-10-08 2012-04-10 Mallinckrodt Inc. Methylphenidate solution and associated methods of administration and production
WO2005041937A2 (en) 2003-10-23 2005-05-12 Otsuka Pharmaceutical Co., Ltd. Controlled release sterile injectable aripiprazole formulation and method
WO2005070390A2 (en) * 2004-01-21 2005-08-04 Janssen Pharmaceutica N.V. Mitratapide oral solution
EP1933814A2 (en) 2005-09-15 2008-06-25 Elan Pharma International Limited Nanoparticulate aripiprazole formulations
CN101351192A (zh) * 2006-01-05 2009-01-21 特瓦制药工业有限公司 阿立哌唑的湿法制粒的药用组合物
JP2008531738A (ja) * 2006-01-05 2008-08-14 テバ ファーマシューティカル インダストリーズ リミティド アリピプラゾールの乾燥製剤
JP4892264B2 (ja) * 2006-03-30 2012-03-07 高田製薬株式会社 リスペリドン水性液剤
US20100021891A1 (en) * 2006-06-12 2010-01-28 Bernard Lerer Rgs2 genotypes associated with extrapyramidal symptoms induced by antipsychotic medication
GB0618879D0 (en) 2006-09-26 2006-11-01 Zysis Ltd Pharmaceutical compositions
HUE036214T2 (hu) * 2007-07-31 2018-06-28 Otsuka Pharma Co Ltd Eljárások aripiprazol-szuszpenzió és fagyasztva szárított készítmény elõállítására
WO2009042166A1 (en) * 2007-09-25 2009-04-02 Panacos Pharmaceuticals, Inc. Liquid bevirimat dosage forms for oral administration
GB2456183A (en) * 2008-01-04 2009-07-08 Gw Pharma Ltd Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
NZ617066A (en) 2008-12-23 2015-02-27 Gilead Pharmasset Llc Nucleoside analogs
PA8855601A1 (es) 2008-12-23 2010-07-27 Forformidatos de nucleósidos
WO2010075554A1 (en) 2008-12-23 2010-07-01 Pharmasset, Inc. Synthesis of purine nucleosides
TWI583692B (zh) 2009-05-20 2017-05-21 基利法瑪席特有限責任公司 核苷磷醯胺
JP5664871B2 (ja) * 2009-06-19 2015-02-04 株式会社 メドレックス アリピプラゾールと有機酸を有効成分とする外用剤組成物
TR201000948A1 (tr) 2010-02-09 2011-08-22 Sanovel İlaç San.Ve Ti̇c.A.Ş. Aripiprazol formülasyonları.
UY33312A (es) 2010-03-31 2011-10-31 Pharmasset Inc Fosforamidato de nucleosido de purina
US8563530B2 (en) 2010-03-31 2013-10-22 Gilead Pharmassel LLC Purine nucleoside phosphoramidate
CL2011000718A1 (es) 2010-03-31 2012-04-09 Gilead Pharmasset Llc Proceso para la preparacion de compuestos fosforados enantiomericos.
WO2012075140A1 (en) 2010-11-30 2012-06-07 Pharmasset, Inc. Compounds
RS55434B1 (sr) 2011-03-18 2017-04-28 Alkermes Pharma Ireland Ltd Injektabilne farmaceutske kompozicije koje sadrže antipsihotik koji je nerastvorljiv u vodi, sorbitan laurat i polisorbat 20
JO3410B1 (ar) * 2011-06-07 2019-10-20 Otsuka Pharma Co Ltd تركيبة أريبيبرازول مجفف بالتبريد
GB2505860B (en) * 2011-06-27 2018-10-31 Shanghai Zhongxi Pharmaceutical Corp Aripiprazole medicament formulation and preparation method therefor
CN102846616B (zh) * 2011-06-27 2015-05-06 上海中西制药有限公司 一种阿立哌唑制剂及其制备方法
TWI679977B (zh) * 2011-10-19 2019-12-21 大塚製藥股份有限公司 口服溶液
ES2764383T3 (es) 2012-03-19 2020-06-03 Alkermes Pharma Ireland Ltd Composiciones farmacéuticas que comprenden ésteres de glicerol
WO2013142205A1 (en) 2012-03-19 2013-09-26 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising benzyl alcohol
AU2013235519C1 (en) 2012-03-19 2018-04-26 Alkermes Pharma Ireland Limited Pharmaaceutical compositions comprising fatty acid esters
JOP20200109A1 (ar) 2012-04-23 2017-06-16 Otsuka Pharma Co Ltd مستحضر قابل للحقن
US20150174247A1 (en) * 2012-06-29 2015-06-25 Maruishi Pharmaceutical Co., Ltd. Oral pharmaceutical preparation of aripiprazole
JP5341282B1 (ja) * 2012-06-29 2013-11-13 丸石製薬株式会社 アリピプラゾールの経口医薬製剤
KR101571670B1 (ko) * 2012-08-08 2015-11-25 주식회사 씨엠지제약 아리피프라졸을 포함하는 경구용 속용 필름 제제
ES2792149T3 (es) 2012-09-19 2020-11-10 Alkermes Pharma Ireland Ltd Composiciones farmacéuticas que tienen estabilidad de almacenamiento mejorada
MY179191A (en) * 2012-09-26 2020-10-30 Pfizer Apixaban liquid formulations
US8568747B1 (en) 2012-10-05 2013-10-29 Silvergate Pharmaceuticals, Inc. Enalapril compositions
WO2014059363A1 (en) * 2012-10-11 2014-04-17 Antrim Pharmaceuticals Llc Oral solution formulations of aripiprazole
EP2908859B1 (en) 2012-10-16 2017-05-17 Arven Ilac Sanayi ve Ticaret A.S. Aripiprazole formulations
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
JP6203682B2 (ja) * 2013-07-10 2017-09-27 共和薬品工業株式会社 アリピプラゾール含有水性液剤
CN103393594A (zh) * 2013-08-22 2013-11-20 万特制药(海南)有限公司 一种新的阿立哌唑的制剂组合物
WO2015143145A1 (en) 2014-03-20 2015-09-24 Alkermes Pharma Ireland Limited Aripiprazole formulations having increased injection speeds
WO2016189504A1 (en) * 2015-05-28 2016-12-01 Leiutis Pharmaceuticals Pvt Ltd Non-lyophilized compositions of aripiprazole and methods of preparation thereof
JP6039849B1 (ja) * 2015-06-12 2016-12-07 高田製薬株式会社 アリピプラゾール含有内用液剤
WO2017025930A1 (en) * 2015-08-12 2017-02-16 Ftf Pharma Private Limited Oral solution of aripiprazole
US9463183B1 (en) 2015-10-30 2016-10-11 Silvergate Pharmaceuticals, Inc. Lisinopril formulations
US9669008B1 (en) 2016-03-18 2017-06-06 Silvergate Pharmaceuticals, Inc. Enalapril formulations
CN108434146A (zh) * 2017-02-16 2018-08-24 天津国际生物医药联合研究院 一种hiv-1整合酶抑制剂的溶液剂及其制备方法和应用
CN109498556A (zh) * 2017-09-15 2019-03-22 万特制药(海南)有限公司 阿立哌唑口服溶液及其制备方法
JP7384812B2 (ja) 2018-03-05 2023-11-21 アルカームス ファーマ アイルランド リミテッド アリピプラゾール投与戦略
CN112666267B (zh) * 2019-10-15 2023-09-26 上海上药中西制药有限公司 一种阿立哌唑药品有关物质的检测方法
JP2023173950A (ja) * 2022-05-27 2023-12-07 同仁医薬化工株式会社 経口液剤

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU843739A3 (ru) † 1978-02-17 1981-06-30 Карл Томэ Гмбх (Фирма) Способ получени карбостириловыхили ОКСиНдОлОВыХ пРОизВОдНыХ
JPS54130587A (en) 1978-03-30 1979-10-09 Otsuka Pharmaceut Co Ltd Carbostyryl derivative
PH17194A (en) * 1980-03-06 1984-06-19 Otsuka Pharma Co Ltd Novel carbostyril derivatives,and pharmaceutical composition containing the same
JPS5959663A (ja) † 1982-09-29 1984-04-05 Otsuka Pharmaceut Co Ltd カルボスチリル誘導体−シクロデキストリン包接化合物
US5006528A (en) * 1988-10-31 1991-04-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
DE3933027A1 (de) * 1989-09-29 1991-04-11 Schering Ag Kombinationspraeparat mit antithrombotischer wirkung
JP3265680B2 (ja) * 1992-03-12 2002-03-11 大正製薬株式会社 経口製剤用組成物
US5457099A (en) † 1992-07-02 1995-10-10 Sawai Pharmaceutical Co., Ltd. Carbostyril derivatives and antiallergic agent
TW254855B (is) 1993-07-28 1995-08-21 Otsuka Pharma Co Ltd
IL132096A0 (en) * 1997-03-31 2001-03-19 Johnson & Johnson Consumer Solvent system for enhanced penetration of pharmaceutical compounds
US20030077227A1 (en) * 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
JP2002524397A (ja) * 1998-09-03 2002-08-06 アルサイド コーポレーション 耐凍結性の局所用殺菌剤及びそれに関連する方法
CA2311734C (en) * 2000-04-12 2011-03-08 Bristol-Myers Squibb Company Flash-melt oral dosage formulation
US20020076437A1 (en) * 2000-04-12 2002-06-20 Sanjeev Kothari Flashmelt oral dosage formulation

Also Published As

Publication number Publication date
IS2863B (is) 2013-12-15
NO20034705L (no) 2003-11-28
KR100909329B1 (ko) 2009-07-24
EE05581B1 (et) 2012-10-15
HUP0303946A3 (en) 2005-06-28
ATE537831T1 (de) 2012-01-15
CZ306181B6 (cs) 2016-09-14
NZ528550A (en) 2005-03-24
WO2002085366A1 (en) 2002-10-31
BG66177B1 (bg) 2011-11-30
AU2002254722B2 (en) 2006-11-09
CN1512884B (zh) 2010-05-26
EP2436384B2 (en) 2018-05-23
BR0208986A (pt) 2004-04-20
NO324606B1 (no) 2007-11-26
DK1381367T3 (da) 2012-04-10
MXPA03009728A (es) 2004-01-29
EP2436384A3 (en) 2012-09-19
PL364666A1 (en) 2004-12-13
US20020193438A1 (en) 2002-12-19
EP1381367A4 (en) 2009-07-01
EP2436384A2 (en) 2012-04-04
MY129350A (en) 2007-03-30
UY27273A1 (es) 2002-11-29
KR20030096332A (ko) 2003-12-24
US6977257B2 (en) 2005-12-20
JP4401077B2 (ja) 2010-01-20
NO20034705D0 (no) 2003-10-21
SK287948B6 (sk) 2012-06-04
PT1381367E (pt) 2012-03-01
HK1058316A1 (en) 2004-05-14
IL158202A0 (en) 2004-05-12
TWI337865B (en) 2011-03-01
HK1168792A1 (en) 2013-01-11
RS52082B (sr) 2012-06-30
EP1381367B1 (en) 2011-12-21
CY1112606T1 (el) 2016-02-10
EP1381367A1 (en) 2004-01-21
HUP0303946A2 (hu) 2004-04-28
UA76144C2 (uk) 2006-07-17
CN1512884A (zh) 2004-07-14
ES2377855T3 (es) 2012-04-02
EE200300523A (et) 2004-02-16
BG108216A (bg) 2004-12-30
EP2436384B1 (en) 2015-06-10
HRP20030870B1 (en) 2011-10-31
PE20021086A1 (es) 2002-12-14
CZ20032821A3 (cs) 2004-09-15
HRP20030870A2 (en) 2004-06-30
GEP20053602B (en) 2005-08-10
ZA200307797B (en) 2004-10-06
IL158202A (en) 2008-04-13
YU84703A (sh) 2006-08-17
SK12642003A3 (sk) 2004-07-07
CA2445276A1 (en) 2002-10-31
RU2295960C2 (ru) 2007-03-27
PL206882B1 (pl) 2010-10-29
JP2004532225A (ja) 2004-10-21
CA2445276C (en) 2009-10-13
AR033168A1 (es) 2003-12-03
HU230456B1 (hu) 2016-07-28
RU2003132426A (ru) 2005-04-20

Similar Documents

Publication Publication Date Title
IS6994A (is) Arípíprazóllausn til gjafar um munn
IL159725A0 (en) Pharmaceutical compositions containing benzimidazole derivatives
NO20033384L (no) Farmasoytisk formulering
NO20033556L (no) Farmasöytiske formuleringer
NO20041315L (no) Medikamentavleveringssystem
FI20011478L (fi) Farmaseuttinen koostumus
NO20033785D0 (no) Farmasöytisk formulering
IS7481A (is) Epóthílon til gjafar um munn
NO20035627D0 (no) Farmasöytisk formulering
IS7114A (is) Miðlar gegn sykursýki til inntöku um munn
EE200300589A (et) Ravimkoostised
DE50209245D1 (de) Neuroprotektives medikament
DE60203537D1 (de) 5ht1-rezeptoragonist enthaltendes arzneimittel
NO20034556D0 (no) Imidazotriazinon-holdige sammensetninger for nasal administrering
IS7097A (is) Lyfjablanda til að gefa fúlvestrant í vöðva
NO20041485L (no) Farmasoytisk formulering omfattende (R)-bicalutamid
NO20043007L (no) Farmasoytisk suspensjon for oral administrering
EP1361866A4 (en) EMULSIONS AS SOLID DOSAGE FORMS FOR ORAL ADMINISTRATION
HUP0200253A3 (en) Pharmaceutical compositions for combination therapy
FI20012242A0 (fi) Uudet farmaseuttiset yhdisteet
EP1413314A4 (en) MEDICAL COMPOSITIONS
NO20041236L (no) Farmasoytisk formulering
NO20034445L (no) Videosystem for tannleger
SE0103116D0 (sv) Pharmaceutical combination
SE0103565D0 (sv) Pharmaceutical formulation